Therefore, it is suitable to study the effect of ACE inhibitors and angiotensin II type I-receptor blockers that are used to treat diabetics and can result in upregulation of hACE-2, thereby potentially sensitizing patients for severe SARS-CoV-2 infection48. The gene discussed is ACE; the disease is COVID-19.